

## Chapter 44

### REFERENCES

1. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. *J Am Geriatr Soc*. 2007;55:1056-1065.
2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. *JAMA*. 2010;303:2043-2050.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560-2572.
4. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. *Cardiol Clin*. 2010;28:609-622.
5. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *J Am Coll Cardiol*. 2007;50:1707-1732.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003.
7. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*. 2005;366:895-906.
8. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008;359:2417-2428.
9. Chobanian AV. Shattuck Lecture. The hypertension paradox—more uncontrolled disease despite improved therapy. *N Engl J Med*. 2009;361:878-887.
10. Reyes AJ, Taylor SH. Diuretics in cardiovascular therapy: new clinicopharmacological bases that matter. *Cardiovasc Drugs Ther*. 1999;13:371-398.
11. Brater DC. Pharmacology of diuretics. *Am J Med Sci*. 2003;319:38-50.
12. Acelajado MC, Oparil S. Hypertension in the elderly. *Clin Geriatr Med*. 2009;25:391-412.
13. Jackson E. *Diuretics*. 11th ed. New York, NY: McGraw-Hill; 2005.
14. Padilla MC, Armas-Hernandez MJ, Hernandez RH, Israili ZH, Valasco M. Update of diuretics in the treatment of hypertension. *Am J Ther*. 2007;14:154-160.
15. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. *Circulation*. 2003;108:1790-1794.
16. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*. 2009;119:e391-e479.
17. Hirsch IA, Tomlinson DL, Slogoff S, Keats AS. The overstated risk of preoperative hypokalemia. *Anesth Analg*. 1988;67:131-136.
18. Reis DJ. Neuron and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. *J Cardiovasc Pharmacol*. 1996;27(Suppl 3):S11-S18.
19. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. *Anesthesiology*. 2000;93:1345-9.
20. Dorman BH, Zucker JR, Verrier ED, Gartman DM, Slachman FN. Clonidine improves perioperative myocardial ischemia, reduces anesthetic requirement, and alters hemodynamic parameters in patients undergoing coronary artery bypass surgery. *J Cardiothorac Vasc Anesth*. 1993;7:386-395.
21. Morris J, Acheson M, Reeves M, Myles PS. Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. *Br J Anaesth*. 2005;95:183-188.
22. Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev*. 2003:CD002024.
23. Wijeyesundera DN, Bender JS, Beattie WS. Alpha-2 adrenergic agonists for the prevention of cardiac complications among

- patients undergoing surgery. *Cochrane Database Syst Rev*. 2009;CD004126.
24. Ebert T, Maze M. Dexmedetomidine: another arrow for the clinician's quiver. *Anesthesiology*. 2004;101:568-570.
  25. Carollo DS, Nossaman BD, Ramadhani U. Dexmedetomidine: a review of clinical applications. *Curr Opin Anaesthesiol*. 2008;21:457-461.
  26. Arcangeli A, D'Alo C, Gaspari R. Dexmedetomidine use in general anaesthesia. *Curr Drug Targets*. 2009;10:687-695.
  27. Wijesundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med*. 2003;114:742-752.
  28. Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazero on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazero Trial (EMIT). *Anesthesiology*. 1999;91:951-961.
  29. Kaplan NM, Opie LH. *Antihypertensive Drugs*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005.
  30. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*. 2003;349:2387-2398.
  31. Prys-Robert C. Pheochromocytoma—recent progress in its management. *Br J Anaesth*. 2000;85:44-57.
  32. Subhani M, Sridhar S, DeCristofaro JD. Phentolamine use in a neonate for the prevention of dermal necrosis caused by dopamine: a case report. *J Perinatol*. 2001;21:324-36.
  33. Zanolini P, Hill L. *Vasodilators*. Philadelphia, PA: Churchill Livingstone; 2003.
  34. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med*. 2004;351:2049-2057.
  35. Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. *Circulation*. 2007;115:1747-1753.
  36. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. *J Clin Hypertens (Greenwich)*. 2004;6:283-287.
  37. Sica DA, Gehr TW. Direct vasodilators and their role in hypertension management: minoxidil. *J Clin Hypertens (Greenwich)*. 2001;3:110-114.
  38. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. *Am J Health Syst Pharm*. 2009;66:1343-1352.
  39. Friederich JA, Butterworth JF. Sodium nitroprusside: twenty years and counting. *Anesth Analg*. 1995;81:152-162.
  40. Dietrick GV, Heesen M, Boldt J, Hempelmann G. Platelet function and adrenoceptors during and after induced hypotension using nitroprusside. *Anesthesiology*. 1996;85:1334-1340.
  41. Lustik SJ, Papadakis PJ, Jackman KV, Rubery PT Jr, Kaplan KL, Chibber AK. Nicardipine versus nitroprusside for deliberate hypotension during idiopathic scoliosis repair. *J Clin Anesth*. 2004;16:25-33.
  42. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. *N Engl J Med*. 2001;345:1548-1557.
  43. Devlin JW, Seta ML, Kanji S, Somerville AL. Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. *Ann Pharmacother*. 2004;38:755-759.
  44. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. *Am J Kidney Dis*. 2007;49:56-68.
  45. Landoni G, Biondi-Zoccai GG, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. *J Cardiothorac Vasc Anesth*. 2008;22:27-33.
  46. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. *JAMA*. 2002;287:1531-1540.
  47. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. *N Engl J Med*. 2000;343:246-253.
  48. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. *JAMA*. 2005;293:1900-1905.
  49. Yancy CW, Krum H, Massie BM, et al. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. *Am Heart J*. 2007;153:478-484.
  50. Opie L, Poole-Wilson P, Pfeffer M. *Angiotensin-Converting Enzyme Inhibitors, Angiotensin-II Receptor Blockers, and Aldosterone Antagonists*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005.
  51. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med*. 2004;351:585-592.
  52. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? *Arch Intern Med*. 2000;160:685-693.
  53. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet*. 2000;355:253-259.
  54. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004;43:S1-S290.
  55. Jessup M, Abraham WT, Casey DE, et al. 1009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*. 2009;119:1977-2016.
  56. Palardy M, Ducharme A, O'Meara E. Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. *Curr Heart Fail Rep*. 2007;4:190-197.
  57. Vermees E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. *Circulation*. 2003;107:2926-2931.
  58. Galletti F, Strazzullo P, Capaldo B, et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trnadolapril Italian Study (TRIS). *J Hypertens*. 1999;17:439-445.

59. Burnier M, Brunner HR. Angiotensin II receptor antagonists. *Lancet*. 2000;355:637-645.
60. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:1004-1010.
61. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*. 2001;345:16667-16675.
62. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003;349:1893-1906.
63. Deedwania PC. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. *Cardiol Clin*. 2005;23:139-152.
64. Van Ruhlsvier EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. *Arch Intern Med*. 1998;158:2063-2065.
65. Augoustides JG. Angiotensin blockade and general anesthesia: so little known, so far to go. *J Cardiothorac Vasc Anesth*. 2008;22:177-179.
66. Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. *Anesthesiology*. 1994;81:299-307.
67. Khetarpal S, Khodaparast O, Shanks A, O'Reilly M, Tremper KK. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy hypotension in noncardiac surgery. *J Cardiothorac Vasc Anesth*. 2008;22:180-186.
68. Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. *Anesth Analg*. 2005;100:636-644.
69. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardio-protective effects of direct renin inhibition: a systemic literature review. *J Hypertens*. 2009;27:2321-2331.
70. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens*. 2007;20:11-20.
71. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. *J Hypertens*. 2007;25:217-226.
72. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardio-protective effects of direct renin inhibition: a systemic literature review. *J Hypertens*. 2009;27:2321-2331.
73. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. *N Engl J Med*. 1997;336:525-533.
74. Poole-Wilson P, Opie LH. Digitalis, acute inotropes, and inotropic dilators. Acute and chronic heart failure. In: Opie LH, Gersh BJ, eds. *Drugs for the Heart*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005.
75. Taboulet P, Baud FJ, Bismuth C, Vicaut E. Acute digitalis intoxication—is pacing still appropriate? *J Toxicol*. 1993;31:261-273.
76. Rabetory GM, Price CA, Findlay JW, Sailstad JM. Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis. *Am J Nephrol*. 1990;10:518-521.
77. Atlee J. *Perioperative Cardiac Dysrhythmias*. Chicago, IL: Mosby-Year Book; 1990.
78. Nossaman VE, Nossaman BD, Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. *Cardiol Rev*. 2010;18:190-197.
79. Brown BG. Response of normal and diseased epicardial coronary arteries to vasoactive drugs: quantitative arteriographic studies. *Am J Cardiol*. 1985;56:23E-29E.
80. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. *J Pharmacol Exp Ther*. 1981;218:739-749.
81. Zhou RH, Frishman WH. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease? *Cardiol Rev*. 2010;18:198-203.
82. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della sopravvivenza nell'infarto Miocardico. *Lancet*. 1994;343:1115-1122.
83. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet*. 1995;345:669-685.
84. Thomas GR, DiFabio JM, Gori T, Parker JK. Once daily therapy with isosorbide-5-monoitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. *J Am Coll Cardiol*. 2007;49:1289-1295.
85. Anderson CM, Woodside KJ, Spencer KA, Hunter GC. Methemoglobinemia: an unusual cause of postoperative cyanosis. *J Vasc Surg*. 2004;39:686-690.
86. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. *Anesth Analg*. 2008;107:1110-1121.
87. Strosberg AD, Pietri-Rouxel F. Function and regulation of the beta<sub>3</sub>-adrenoceptor. *Trends Pharmacol Sci*. 1996;17(10):373-381.
88. Skeberdis VA. Structure and function of beta<sub>3</sub>-adrenergic receptors. *Medicina (Kaunas)*. 2004;40(5):407-413.
89. Frischman W. *Clinical Pharmacology of Beta-Adrenoceptor Blocking Drugs*. 2nd ed. Norwalk, CT: Appleton-Century-Crofts; 1984.
90. Kostis JB, DeFelice EA. Beta blockers in the treatment of hypertension. In: Kostis JB, DeFelice EA, eds. *The Pharmacological Treatment of Cardiovascular Disease*. New York, NY: Elsevier Science Publishing Co; 1986:3-28.
91. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. *Pharmacol Ther*. 2003;100(3):215-234.
92. London MJ, Zaugg M, Schaub MC, Spahn DR. Perioperative beta-adrenergic receptor blockade: physiologic foundations and clinical controversies. *Anesthesiology*. 2004;100(1):170-175.
93. Keller, KB, Lemberg L. Prinzmetal's angina. *Am J Crit Care*. 2004;13(4):350-354.
94. Singh BN. Beta-adrenergic blockers as antiarrhythmic and anti-fibrillatory compounds: an overview. *J Cardiovasc Pharmacol Ther*. 2005;10(Suppl 1):S3-S14.



95. Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. *Cardiol Clin.* 2004;22(1):35-45.
96. Singh SN, Patrick J, Patrick J. Antiarrhythmic drugs. *Curr Treat Options Cardiovasc Med.* 2004;6(5):357-364.
97. Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. *Am J Cardiol.* 1990;66(16):66G-70G.
98. Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. *N Engl J Med.* 2004;350(13):1320-1327.
99. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. *J Am Coll Cardiol.* 2004;44(3):497-502.
100. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med.* 1991;151(9):1769-1776.
101. Frishman WH. Beta-adrenergic blockers. *Med Clin North Am.* 1988;72(1):37-81.
102. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF study group. *JAMA.* 2000;283(10):1295-1302.
103. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. *Circulation.* 2000;101(4):378-384.
104. Carney RM, Rich MW, teVelde A, Saini J, Clark K, Freedland KE. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. *Am J Med.* 1987;83(2):223-226.
105. McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. *Drugs.* 2002;62(18):2677-2696.
106. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies—CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. *Am Heart J.* 2002;143(2):301-307.
107. Channer KS, James MA, MacConnell T, Rees JR. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. *Br J Clin Pharmacol.* 1994;37(1):53-57.
108. Strickberger SA, Fish RD, Lamas GA, et al. Comparison of effects of propranolol versus pindolol on sinus rate and pacing frequency in sick sinus syndrome. *Am J Cardiol.* 1993;71(1):53-56.
109. Rosendorff C. Beta-blocking agents with vasodilator activity. *J Hypertens Suppl.* 1993;11(4):S37-S40.
110. Ornstein E, Young WL, Ostapkovich N, Matteo RS, Diaz J. Are all effects of esmolol equally rapid in onset? *Anesth Analg.* 1995;81(2):297-300.
111. Weiskopf RB. Cardiovascular effects of desflurane in experimental animals and volunteers. *Anaesthesia.* 1995;50(Suppl):14-17.
112. Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon JY. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. *Am J Cardiol.* 2000;85(12):1467-1471.
113. Pujet JC, Dubreuil C, Fleury B, Provendier O, Abella ML. Effects of celiprolol, a cardioselective beta-blocker, on respiratory function in asthmatic patients. *Eur Respir J.* 1992;5(2):196-200.
114. Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. *Congest Heart Fail.* 2002;8(3):173-177, 190.
115. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med.* 1996;334(21):1349-1355.
116. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. *Circulation.* 1996;94(11):2807-2816.
117. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet.* 2003;362(9377):7-13.
118. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med.* 2001;344(22):1659-1667.
119. Cockcroft J. Nebivolol: a review. *Expert Opin Pharmacother.* 2004;5(4):893-899.
120. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J.* 2005;26(3):215-225.
121. Cheng JW. Nwbiolol: a third-generation beta-blocker for hypertension. *Clin Ther.* 2009;31(3):447-462.
122. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med.* 1996;335(23):1713-1720.
123. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia: McSPI Research Group. *Anesthesiology.* 1998;88(1):7-17.
124. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative  $\beta$  blockers in patients having non-cardiac surgery: a meta-analysis. *Lancet.* 2008;372(9654):1962-1976.
125. POISE Study Group; Devereaux PF, Yang H, Yusuf S, et al. Effects of extended release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomized controlled trial. *Lancet.* 2008;371(9627):1839-1847.
126. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery: Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med.* 1999;341:1789-1794.
127. Poldermans D, Boersma E, Bax JJ, et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. *Eur Heart J.* 2001;22:1353-1358.
128. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients

- undergoing noncardiac surgery. A randomized controlled trial (DECREASE-IV). *Ann Surg.* 2009;249(6):921-926.
129. Badgett RG, Lawrence VA, Cohn SL, et al. Variations in pharmacology of  $\beta$ -1 blockers may contribute to heterogeneous results in trials of perioperative  $\beta$ -1 blockade. *Anesthesiology.* 2010;113(3):585-592.
  130. Fleischmann KE, Beckman JA, Buller CE, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine; Society for Vascular Surgery. 2009 ACCF/AHA focused update on perioperative beta blockade. *J Am Coll Cardiol.* 2009;54(22):2102-2128.
  131. van Lier F, Schouten O, van Domburg RT, et al. Effect of beta-blocker use on stroke after noncardiac surgery. *Am J Cardiol.* 2009;104(3):429-433.
  132. Henriksson BA, Biber B, Häggendal J, Lundberg D, Pontén J, Rosén KG. Cardiovascular effects of enflurane and asphyxia during long-term beta 1-adrenoceptor blockade. *Acta Anaesthesiol Scand.* 1985;29(4):363-370.
  133. Abel M, Book WJ, Eisenkraft JB. Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management. *Drug Saf.* 1994;10(6):420-438.
  134. Lesser JB, Sanborn KV, Valskys R, Kuroda M. Severe bradycardia during spinal and epidural anesthesia recorded by an anesthesia information management system. *Anesthesiology.* 2003;99(4):859-866.
  135. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. *N Engl J Med.* 1999;341(19):1447-1457.
  136. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. *Br J Pharmacol.* 1998;125(5):1005-1012.
  137. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. *N Engl J Med.* 2004;351(14):1425-1436.
  138. Wigley FM. Clinical practice. Raynaud's phenomenon. *N Engl J Med.* 2002;347(13):1001-1008.
  139. Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. *Am Heart J.* 1985;109(2):210-217.
  140. Jespersen CM. The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. *Eur Heart J.* 1993;14(4):540-545.
  141. Singh BN, Nademane K, Baky SH. Calcium antagonists. Clinical use in the treatment of arrhythmias. *Drugs.* 1983;25(2):125-153.
  142. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. *Am J Cardiol.* 1980;46(6):1047-1058.
  143. Kitakaze M, Asanuma H, Takashima S, et al. Nifedipine-induced coronary vasodilatation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. *Circulation.* 2000;101(3):311-317.
  144. Ellrodt AG, Ault MJ, Riedinger MS, Murata GH. Efficacy and safety of sublingual nifedipine in hypertensive emergencies. *Am J Med.* 1985;79(4A):19-25.
  145. Schwartz JB, Caputo G, Abbott J. Early experience with dobutamine stress testing and cardiac cine-tomographic imaging in the elderly: antianginal effects of nifedipine-GITS. *J Am Geriatr Soc.* 1993;41(9):967-974.
  146. Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta blockers for optimal antianginal therapy. *Clin Cardiol.* 1994;17(8):415-421.
  147. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide. *Circulation.* 1990;82:1954-1961.
  148. Ishikawa K, Nakai S, Takenaka T, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. *Circulation.* 1997;95(10):2368-2373.
  149. Rose JC, Mayer SA. Optimizing blood pressure in neurologic emergencies. *Neurocrit Care.* 2004;1(3):287-300.
  150. Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. *Am J Health Syst Pharm.* 2004;61(16):1661-1673; quiz 1674-1675.
  151. Kwak YL, Oh YJ, Bang SO, Lee JH, Jeong SM, Hong YW. Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary artery bypass graft surgery. *J Int Med Res.* 2004;32(4):342-350.
  152. Rabinstein AA, Wijdicks EF. Cerebral vasospasm in subarachnoid hemorrhage. *Curr Treat Options Neurol.* 2005;7(2):99-107.
  153. Fischell TA, Maheshwari A. Current applications for nicardipine in invasive and interventional cardiology. *J Invasive Cardiol.* 2004;16(8):428-432.
  154. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev.* 2000(2):CD000277.
  155. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. *Cochrane Database Syst Rev.* 2000(2):CD001928.
  156. de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. *Am Heart J.* 2000;139(2 Pt 1):185-194.
  157. Taylor SH. Usefulness of amlodipine for angina pectoris. *Am J Cardiol.* 1994;73(3):28A-33A.
  158. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet.* 1997;350(9080):757-764.
  159. Nguyen HM, Ma K, Pham DQ. Clevidipine for the treatment of severe hypertension in adults. *Clin Ther.* 2010;32(1):11-23.
  160. Ndefo UA, Erowele GI, Ebiasah R, Green W. Clevidipine: a new intravenous option for the management of acute hypertension. *Am J Health Syst Pharm.* 2010;67(5):351-360.
  161. Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. *Pharmacotherapy.* 2010;30(5):515-528.
  162. Lee DS, Goodman S, Dean DM, et al. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. *Am Heart J.* 2002;144(1):60-67.

163. Frishman WH. Mibefradil: a new selective t-channel calcium antagonist for hypertension and angina pectoris. *J Cardiovasc Pharmacol Ther.* 1997;2(4):321-330.
164. Glaser S, Steinbach M, Opitz C, Wruck U, Kleber FX. Torsades de pointes caused by mibefradil. *Eur J Heart Fail.* 2001;3(5):627-630.
165. Sasaki J, Ogihara T, Yokoyama M, et al. Comparative effects of monatepil, a novel calcium antagonist with alpha 1-adrenergic-blocking activity, and nitrendipine on lipoprotein and carbohydrate metabolism in patients with hypertension. *Am J Hypertens.* 1994;7(10 Pt 2):161S-166S.
166. Hollingshead LM, Faulds D, Fitton A. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. *Drugs.* 1992;44(5):835-857.
167. Engelman RM, Hadji-Rousou I, Breyer RH, Whittredge P, Harbison W, Chircop RV. Rebound vasospasm after coronary revascularization in association with calcium antagonist withdrawal. *Ann Thorac Surg.* 1984;37(6):469-472.
168. Marijic J, Bosnjak ZJ, Stowe DF, Kampine JP. Effects and interaction of verapamil and volatile anesthetics on the isolated perfused guinea pig heart. *Anesthesiology.* 1988;69(6):914-922.
169. Humphrey LS, Blanck TJ. Intraoperative use of verapamil for nitroglycerin—refractory myocardial ischemia. *Anesth Analg.* 1985;64(1):68-71.
170. Lee MK, Lee IO, Kong MH, Kim NS, Choi YS, Lim SH. Comparative effects of diltiazem with enflurane or desflurane on myocardial contractility and heart rate in the isolated rat hearts. *Acta Anaesthesiol Sin.* 2000;38(4):173-179.
171. Rosenthal T, Ezra D. Calcium antagonists. Drug interactions of clinical significance. *Drug Saf.* 1995;13(3):157-187.
172. Gallenberg LA, Stowe DF, Kampine JP, Bosnjak ZJ. Effects of nifedipine with isoflurane, halothane, or enflurane on automaticity, conduction, and contractility in isolated guinea pig hearts. *Anesthesiology.* 1993;78(6):1112-1119; discussion 23A-24A.
173. Nishiyama T, Matsukawa T, Hanaoka K, Conway CM. Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. *Can J Anaesth.* 1997;44(10):1071-1076.
174. Chung F, Houston PL, Cheng DC, et al. Calcium channel blockade does not offer adequate protection from perioperative myocardial ischemia. *Anesthesiology.* 1988;69(3):343-347.
175. Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. *Circulation.* 2003;107(6):817-823.
176. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. *Eur Heart J.* 2005;26(23):2529-2536.
177. Fasullo S, Cannizzaro S, Maringhini G, et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. *J Card Fail.* 2009;15(10):856-863.
178. Riccioni G. Ivabradine: from molecular basics to clinical effectiveness. *Adv Ther.* 2010;27(3):160-167.
179. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial. *Lancet.* 2002;359(9314):1269-1275.
180. Chaitman BR, Pepine CJ, Parker JO, et al; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. *JAMA.* 2004;291(3):309-316.
181. Chaitman BR, Skettino SL, Parker JO, et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. *J Am Coll Cardiol.* 2004;43(8):1375-1382.
182. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. *Eur Heart J.* 2001;22(24):2267-2274.
183. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. *J Clin Pharmacol.* 1984;24(4):129-147.
184. The AVID investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID)—rationale, design, and methods. *Am J Cardiol.* 1995;75(7):470-475.
185. Gleva MJ. Antiarrhythmic Agents. In: Evers AS, Maze M eds. *Anesthetic Pharmacology: Physiologic Principles and Clinical Practice.* Philadelphia: Churchill Livingstone 2003: 621-631.
186. Gallik D, Altamirano J, Singh BN. Restoring sinus rhythm in patients with atrial flutter and fibrillation: pharmacologic or electrical cardioversion? *J Cardiovasc Pharmacol Ther.* 1997;2(2):135-144.
187. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. *Am J Cardiol.* 2003;91(6A):15D-26D.
188. Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: the clinical considerations. *Int J Cardiol.* 2004;96(1):1-6.
189. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis. *Circulation.* 1991;84(5):1977-1983.
190. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. *Circulation.* 1990;82(4):1106-1116.
191. Roden DM, Reele SB, Higgins SB, et al. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. *Am J Cardiol.* 1980;46(3):463-468.
192. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2005;45(8):1251-1258.
193. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. *N Engl J Med.* 1992;327(4):227-233.
194. Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. *Arch Intern Med.* 1989;149(12):2694-2698.
195. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. *N Engl J Med.* 2002;346(12):884-890.



196. Kapur PA, Grogan DL, Fournier DJ. Cardiovascular interactions of lidocaine with verapamil or diltiazem in the dog. *Anesthesiology*. 1988;68(1):79-85.
197. Duff HJ, Roden D, Primm RK, Oates JA, Woosley RL. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. *Circulation*. 1983;67(5):1124-1128.
198. Woosley RL, Wang T, Stone W, et al. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. *Am Heart J*. 1984;107(5 Pt 2):1058-1065.
199. IMPACT Research Group. International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT): II. Results from 24-hour electrocardiograms. *Eur Heart J*. 1986;7(9):749-759.
200. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med*. 1991;324(12):781-788.
201. Conard GJ, Ober RE. Metabolism of flecainide. *Am J Cardiol*. 1984;53(5):41B-51B.
202. Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. *J Am Coll Cardiol*. 1986;8(3):607-615.
203. McAllister CB, Wolfenden HT, Aslanian WS, Woosley RL, Wilkinson GR. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. *Xenobiotica*. 1986;16(5):483-490.
204. Funck-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. *N Engl J Med*. 1990;322(8):518-525.
205. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. *Circulation*. 1991;84(4):1831-1851.
206. Miller JM, Zipes DP. Therapy for cardiac arrhythmias. In: Zipes DP, Libby P, Borroa RO, Braunwald E, eds. *Braunwald's Heart Disease—A Textbook of Cardiovascular Medicine*. Philadelphia, PA: Elsevier Saunders; 2005:729-731.
207. Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. *N Engl J Med*. 1997;337(25):1785-1791.
208. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. *N Engl J Med*. 1999;341(12):871-878.
209. American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2005;112(24 Suppl):IV1-IV203.
210. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. *Arch Intern Med*. 2000;160(12):1741-1748.
211. Balsler JR. The rational use of intravenous amiodarone in the perioperative period. *Anesthesiology*. 1997;86(4):974-987.
212. Rooney RT, Marijic J, Stommel KA, et al. Additive cardiac depression by volatile anesthetics in isolated hearts after chronic amiodarone treatment. *Anesth Analg*. 1995;80(5):917-924.
213. Feldman HS, Arthur GR, Pitkanen M, Hurley R, Doucette AM, Covino BG. Treatment of acute systemic toxicity after the rapid intravenous injection of ropivacaine and bupivacaine in the conscious dog. *Anesth Analg*. 1991;73(4):373-384.
214. Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. *Am Heart J*. 1999;137(3):388-409.
215. Nattel S, Feder-Elituv R, Matthews C, Nayeypour M, Talajic M. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. *J Am Coll Cardiol*. 1989;13(5):1190-1194.
216. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. *Circulation*. 2002;106(1):75-80.
217. Sakaguchi Y, Sugiyama A, Takao S, Akie Y, Takahara A, Hashimoto K. Halothane sensitizes the guinea-pig heart to pharmacological i(kr) blockade: comparison with urethane anesthesia. *J Pharmacol Sci*. 2005;99(2):185-190.
218. Murray KT. Ibutilide. *Circulation*. 1998;97(5):493-497.
219. Vanderlugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. *Circulation*. 1999;100(4):369-375.
220. Kalus JS, Mauro VF. Dofetilide: a class III-specific antiarrhythmic agent. *Ann Pharmacother*. 2000;34(1):44-56.
221. Martinez EA, Epstein AE, Bass EB. Pharmacologic control of ventricular rate: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. *Chest*. 2005;128(2 Suppl):56S-60S.
222. Gupta AK, Shah CP, Maheshwari A, Thakur RK, Hayes OW, Lokhandwala YY. Adenosine induced ventricular fibrillation in Wolff-Parkinson-White syndrome. *Pacing Clin Electrophysiol*. 2002;25(4 Pt 1):477-480.
223. Eisenach JC, Hood DD, Curry R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. *Anesthesiology*. 2002;96(1):29-34.
224. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*. 1996;335(14):1001-1009.
225. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344(8934):1383-1389.
226. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*. 1998;339(19):1349-1357.
227. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. *J Am Coll Cardiol*. 2000;35(1):1-10.
228. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg*. 2004;39(5):967-975.
229. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. *Circulation*. 2003;107(14):1848-1851.

230. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. *J Am Coll Cardiol.* 2005;45(3):336-342.
231. McGirt MJ, Perler BA, Brooke BS, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. *J Vasc Surg.* 2005;42(5):829-836; discussion 836-837.
232. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. *Chest.* 2005;128(5):3421-3427.
233. Forestier F, Breton Y, Bonnet E, Janvier G. Severe rhabdomyolysis after laparoscopic surgery for adenocarcinoma of the rectum in two patients treated with statins. *Anesthesiology.* 2002;97(4):1019-1021.